Journal of Tongji Medical University

, Volume 18, Issue 4, pp 236–238 | Cite as

Serum lipoprotein (a) concentration in patients with nephrotic syndrome and its clinical implication

  • Yang Xiao
  • Wang Huiling
  • Zhu Zhonghua
  • Deng Anguo


Serum lipoprotein (a) [Lp(a)] concentration was determined in 42 patients with primary nephrotic syndrome (NS) and the relationships between Lp (a) and plasma lipids, apolipoproteins, serum creatinine (Scr), albumin, urinary proteins (Upro) were also analyzed. The results showed that: (1) serum Lp(a) concentrations in the patients with NS were higher than those in healthy controls; (2) the levels of serum Lp(a) were correlated positively with total cholesterol (TO, low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein B (Apo-B), Upros (Upro). It is concluded that the NS patients had the potential risk of suffering from coronary artery disease, glomerular sclerosis and thrombosis. The remission of NS may partially decrease the serum Lp(a) levels. Further studies are needed to explore the prevention and treatment of dislipedemia in patients with NS.

Key words

lipoprotein (a) nephrotic syndrome dislipedemia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ordonez J D, Robert H, Ellen Ket al. The risk of coronary artery disease among patients with the nephrotic syndrome. Kidney Int, 1990, 37: 243Google Scholar
  2. 2.
    Murai A, Miyahara T, Fujimoto Met al. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Athrosclerosis, 1986, 59:199CrossRefGoogle Scholar
  3. 3.
    Appel G B, Blum C B, Chien Set al. The hyperlipidemia of the nephrotic syndrome, relation to plasma albumin concentration, oncotic pressure, and viscosity. N Eng J Med, 1985, 312: 1544Google Scholar
  4. 4.
    Steinberg D, Parthasarphy S, Carew T Eet al. Beyond cholesterol modification of low density lipoprotein that increase its atherogenity. N Engl JMed, 1989, 320:915Google Scholar
  5. 5.
    Brown M S, Goldstein J L. Teaching old dogmas new tricks. Nature, 1987, 330:113PubMedCrossRefGoogle Scholar
  6. 6.
    Galle J, Heinloth A, Schwedler Set al. Effect of HDL and atherogenity lipoprotein on formation of O2 and rennin release in juxtaglomerular cells. Kidney Int, 1997, 51:253PubMedCrossRefGoogle Scholar
  7. 7.
    Dahlen G H, Guyton J R, Arrar Met al. Association of level of lipoprotein (a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation, 1986, 74:758PubMedGoogle Scholar
  8. 8.
    Utermann G. The mysteries of lipoprotein (a). Science, 1989, 246:904PubMedCrossRefGoogle Scholar
  9. 9.
    Knight B L, Perombelon Y F, Soutar A Ket al. Catabolism of Lp (a) in familial hypercholesterolaemic subjects. Atherosclerosis, 1991, 87:227PubMedCrossRefGoogle Scholar
  10. 10.
    Wanner C, Rader D, Barten Wet al. Elevated plasma Lp(a) in patients with the nephrotic syndrome. Ann Inter Med, 1993, 119:263Google Scholar
  11. 11.
    Webb A T, Plant M, Reareley D Aet al. Lipid and Lp(a) concentrations in renal transplant patients. Nephrol Dial Transplant, 1992, 7:636PubMedGoogle Scholar

Copyright information

© Springer 1998

Authors and Affiliations

  • Yang Xiao
    • 1
  • Wang Huiling
    • 1
  • Zhu Zhonghua
    • 1
  • Deng Anguo
    • 1
  1. 1.Department of Nephrology, Xiehe HospitalTongji Medical UniversityWuhan

Personalised recommendations